ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
Announces CFO transition
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
Announces CFO transition...
The 7 Best Penny Stocks to Buy in Q2 2024
Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer.
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Biotechnologies GAAP EPS of -$0.48 misses by $0.15, revenue of $45.78M misses by $2.68M (NASDAQ:ADPT)
Adaptive Biotechnologies press release (ADPT): Q4 GAAP EPS of -$0.48 misses by $0.15. Revenue of $45.78M (-17.1% Y/Y) misses by $2.68M. The MRD business, which
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...
Commit To Buy Adaptive Biotechnologies Corp At $2.50, Earn 9.3% Annualized Using Options
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You?
The Ark Invest founder sees potential in these three under-the-radar stocks.
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from...
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured at ASH....
Commit To Purchase Adaptive Biotechnologies At $2.50, Earn 45.6% Annualized Using Options